Published 2024
| Version v2
Poster
Open
Identification of Molecular Biomarker for the Diagnosis of Ampullary Carcinoma
Authors/Creators
- 1. Rehman Medical College (RMC)
- 2. Precision Medicine Lab, CECOS-RMI
- 3. Institute of Integrative Biosciences, CECOS University
- 4. Centre for Genomic Sciences, Rehman Medical Institute
Description
Ampullary cancers are rare, accounting for only 0.2% of gastrointestinal cancers and approximately 7% of all periampullary cancers. (1) with an incidence of approximately 4 to 10 cases per million population (2). Adenocarcinoma of the ampulla of Vater is the second most common periampullary malignancy. Early diagnosis is important because lymph node status influences survival (3). Currently, only CEA and CA19-9 , non specific biomarkers are used to diagnose Ampullary Carcinoma.
Files
QuratulAin.pdf
Files
(1.4 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:3895129ade2909e8e2b98fc33263607d
|
1.4 MB | Preview Download |
Additional details
References
- 1) Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014;112-115. doi:10.14694/EdBook_AM.2014.34.112
- 2) Albores-Saavedra, J., Schwartz, A. M., Batich, K., & Henson, D. E. (2009). Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. Journal of surgical oncology, 100(7), 598–605. https://doi.org/10.1002/jso.21374
- 3) Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997;225(5):590-600. doi:10.1097/00000658-199705000-00015